Related Experiment Video
Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Drug Development
Vincent O Olughor1, Kemi O Charles-Okhe1, Amany K Ladagu2
1Faculty of Pharmacy, University of Ibadan, Ibadan, Nigeria.
Preventing Alzheimer's disease (AD) involves addressing micronutrient deficiencies and neurotoxin exposure. A nutraceutical therapy could restore nutrient balance and protect against neurodegeneration, potentially preventing FAD.
Area of Science:
- Neuroscience
- Nutritional Science
- Biochemistry
Background:
- Alzheimer's disease (AD) onset is linked to elevated plasma 24-hydroxycholesterol.
- Risk factors for AD progression include micronutrient deficiencies, low antioxidant levels, neurotoxin exposure, and disrupted autophagy.
- These factors can lead to Wallerian-type degeneration of cholinergic neurons, ultimately causing AD.
Purpose of the Study:
- To review risk factors contributing to Alzheimer's disease (AD).
- To explore intervention therapies for reverting these risk factors.
- To establish prevention strategies for AD, focusing on acetylcholine depletion and memory loss.
Main Methods:
- Literature review on risk factors for AD.
- Analysis of intervention therapies for risk factor management.
- Focus on preventing neurodegeneration and neurotransmitter depletion.
Main Results:
- Micronutrient deficiencies (e.g., calcium, iron, vitamin D) can increase neurotoxic lead absorption.
- Low antioxidant levels allow lipophilic neurotoxins to compromise the blood-brain barrier (BBB), leading to neurodegeneration.
- Autophagy dysregulation is implicated in AD and other neurodegenerative diseases.
Conclusions:
- A nutraceutical therapy is proposed for AD prevention.
- This therapy will provide essential nutrients (macro, micro, phyto) to maintain optimal plasma pH (7.35-7.45).
- The formulation aims to prevent the physiological disruptions leading to AD.
More Related Videos
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
Related Concept Videos
Preclinical Development: Overview
Clinical Trials: Overview
Drug Discovery: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
In Vitro Drug Release Testing: Overview, Development and Validation
Drug Regulation